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ABSTRACT
A previously healthy 65-year-old female passenger presented on the 3rd day of her voyage with a small 
facial laceration after she fell and hit her forehead, following sudden blurred vision and dizziness. When 
the ship’s doctor noticed that one pupil was much bigger than the other, he feared intracranial bleeding 
and considered helicopter evacuation. 
Her symptoms had started shortly after she had removed a transdermal scopolamine patch from behind 
her ear. Getting scopolamine from her hands in direct contact with the eye surface caused mydriasis. To 
prevent it, after handling the patch, the hands and the application site should have been washed thoroughly 
with soap and water and dried. 
Only time was needed for the dilated pupil to normalise. 
(Int Marit Health 2016; 67, 3: 159–160)
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CASE REPORT
A previously healthy 65-year-old female passenger on 
a 10-day cruise presented on the 3rd day of her voyage in 
the ship’s medical facility with a slightly oozing, 3-cm cut 
across her left eyebrow, requesting stitches. She had for 
a few hours noticed blurred vision and that her mouth was 
dry. Her blurred vision suddenly became worse, she felt dizzy 
despite calm seas, and when stepping into her bathroom, 
she failed to notice the raised doorstep, stumbled and fell, 
hitting her head against the sink. She did not faint.
At presentation she had the above-mentioned mild 
symptoms, but otherwise felt well and denied having even 
the slightest headache. Clinical and neurological examina-
tions were normal, with one exception: Both her pupils were 
somewhat dilated. When the ship’s doctor prepared to close 
her face wound, he observed — with alarm — that the left 
pupil was nonreactive and bigger than the right one. When 
asked, the patient denied having ever suspected that her 
pupils were unequal in size. 
Recalling that anisocoria with head trauma is a classic 
sign of impending brain herniation, the doctor urgently 
called an experienced maritime-medical consultant ashore 
for advice regarding helicopter evacuation to the nearest 
port of call with medical specialist service (neurosurgeon, 
neurologist or ophthalmologist?). The consultant’s first ques-
tion, “Anything to see behind her ears?” Puzzled, the ship’s 
doctor looked: Nothing. Next question, “Has she taken any 
medication or used any remedies against motion sickness 
this cruise?”.
Indeed she had: Fearing rough weather, she had applied 
a  transdermal scopolamine patch behind one ear a  few 
hours before departure from the first port. She felt fine for 
the next 72 hours, then removed the patch and applied 
a new patch right away. Several hours later she started to 
be bothered by dry mouth and blurred vision. She had been 
informed by her own physician about common side effects, 
so she decided to remove the patch since the sea was calm 
and the weather forecast excellent. Her vision got worse 
after the removal; she felt dizzy, fell and then ended up in 
the ship’s doctor’s office. 
No helicopter was ordered, her hands and post-auricular 
areas were carefully cleaned, and she was released from the 
medical facility with strict instructions to call immediately if 
she got any worse. At follow-up the next day she felt “back to 
normal” and all clinical and neurological findings, including 
pupil size and light reactions, were unremarkable.
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COMMENTS
Head injury combined with anisocoria might suggest 
intracranial bleeding, a condition that can quickly turn into 
a nightmare on a ship in a remote location with limited or 
no possibilities of speedy evacuation to a neurosurgical unit 
ashore [1]. Luckily, in this case it was false alarm.
Anisocoria, or unequal pupil sizes, is a common con-
dition; some degree of pupil difference may be expected 
in at least 1 in 5 clinic patients. The varied causes have 
implications ranging from life-threatening to completely 
benign, and a clinically guided history and examination is 
the first step in establishing a diagnosis [2].
The reason for the enlarged and nonreactive pupil of 
our patient was simply scopolamine, a belladonna alkaloid 
that exerts anticholinergic effects [3]. She must have rubbed 
her eye after removing her second scopolamine patch and 
then scopolamine got in direct contact with the eye surface. 
According to user instructions [4], one scopolamine 
patch should be applied to the hairless area behind one ear 
at least 4 hours before the antiemetic effect is required. It 
is formulated to deliver approximately 1 mg of scopolamine 
over 3 days and should then be replaced. However, in many 
cases the patch is not “empty” after 72 hours, so if one 
patch is applied just after removal of another, the patient 
will get a double dose within a few hours. There will then be 
a higher risk of anticholinergic side effects [5], colloquially 
described as “Blind as a bat, mad as a hatter, red as a beet, 
hot as Hades (or hot as a hare), dry as a bone, the bowel 
and bladder lose their tone, and the heart runs alone” [6].
Our patient had dry mouth and blurred vision after ap-
plying her second patch, most likely due to a  temporary 
double drug dose. Anisocoria after removal of the second 
patch was the probably reason for her poorer vision and 
dizziness later, causing her to stumble, fall and hit her head. 
To prevent mydriasis, after administration of the patch, 
the hands and the application site should be washed thor-
oughly with soap and water and dried [4]. However, if scopol-
amine-associated mydriasis does occur, only time is needed 
for the dilated pupil to normalise. In another scopolamine 
case, investigations not available on ships (computer tomo-
graphy with angiogram and magnetic resonance imaging) 
were done to rule out stroke and aneurysm [3].
Seasickness is not an illness, just an uncomfortable 
condition, but must be taken seriously by ship’s medical 
staff and management. It can adversely affect alertness of 
watch-going officers and crew and decrease the service level 
of hotel staff [7]. Cruise companies want the medical staff 
to handle seasick passengers as emergencies, because 
upset clients are not likely to buy another cruise vacation 
if not quickly and successfully treated.
But although there are plenty of anecdotal cures for full-
blown seasickness, there are hardly any treatment studies 
from which to draw evidence-based conclusions [7]. Preventive 
remedies are better researched, but preferred prophylaxes vary 
around the world; in fact, the drug-of-choice in one country may 
even be banned or not registered at all in another country [7]. 
Transdermal scopolamine was long ago shown to pro-
vide better protection against mild motion sickness than 
placebo and the widely used oral meclizine [8]. Although 
rare [4], scopolamine-induced confusion and hallucinations 
may be dangerous and frightening, particularly at sea, and 
that risk is the main reason for transdermal scopolamine 
patches not being offered on most cruise vessels. But pas-
sengers keep bringing patches on board, often without 
proper instructions for use, so ship’s medical staff must be 
familiar with all remedies against motion sickness and their 
side effects. Many doctors and nurses on large vessels will 
readily agree that side effects from seasick medication are 
now a bigger challenge than seasickness itself. 
Anisocoria at sea is alarming, but without symptoms or 
signs of serious head injury the possibility of a scopolamine 
side effect should be considered and investigated before 
urgent evacuation is arranged.
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